Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning

Bone Marrow Transplant. 2010 Aug;45(8):1369-71. doi: 10.1038/bmt.2009.344. Epub 2009 Dec 7.

Authors

J Kanda, T Ichinohe, T Saito, K Yamashita, T Kondo, T Ishikawa, S Ichiyama, T Uchiyama

PMID: 19966848
DOI: 10.1038/bmt.2009.344

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Bacterial Infections / etiology
Bone Marrow Transplantation / adverse effects
Bone Marrow Transplantation / methods
Bone Marrow Transplantation / mortality
Fluoroquinolones / therapeutic use*
Humans
Middle Aged
Myeloablative Agonists / adverse effects
Myeloablative Agonists / therapeutic use*
Peripheral Blood Stem Cell Transplantation / adverse effects
Peripheral Blood Stem Cell Transplantation / methods
Peripheral Blood Stem Cell Transplantation / mortality
Premedication
Retrospective Studies
Safety-Based Drug Withdrawals*
Survival Analysis
Transplantation Conditioning / adverse effects
Transplantation Conditioning / methods
Transplantation Conditioning / mortality*
Transplantation, Homologous
Young Adult

Substances

Fluoroquinolones
Myeloablative Agonists